Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis

Multiple Sclerosis

Volumn 16, Issue 11, 2010, Pages 1349-1359

  Kavia, R B C ^a   De Ridder, D ^b   Constantinescu, C S ^c   Stott, C G ^d   Fowler, C J ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

^d Porton Down Science Park   (United Kingdom)

Author keywords

cannabinoid; detrusor overactivity; multiple sclerosis; overactive bladder; Sativex

Indexed keywords

CANNABIS; PLACEBO;

ADULT; ARTICLE; BALANCE DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DIARRHEA; DISORIENTATION; DISSOCIATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INCIDENCE; INCONTINENCE QUALITY OF LIFE; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTIPLE SCLEROSIS; NAUSEA; NOCTURIA; OVERACTIVE BLADDER; PARESTHESIA; PHARYNGITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; URINE VOLUME; VOMITING; WEAKNESS;

DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PLANT EXTRACTS; URINARY BLADDER, OVERACTIVE;

EID: 78349253181     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510378020     Document Type: Article

References (36)

1. Abrams P., Cardoza L., Fall M., Griffiths D., Rosier P., Ulmsten U., et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 2002 ; 21: 167-178.
2. Brady CM, DasGupta R., Dalton C., Wiseman OJ, Berkley KJ and Fowler CJ An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004 ; 10: 425-433.
3. Milsom I., Abrams P., Cardoza L., Roberts RG, Thuroff J. and Wein AJ How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001 ; 87: 760-766.
4. Russo E. Cannabis treatments in obstetrics and gynaecology: A historical review. J Cannabis Therapeut 2002 ; 2: 5-35.
5. Russo EB The role of cannabis and cannabinoids in pain management. In: Cole BE, Boswell M (eds) Weiner's Pain Management: A Practical Guide for Clinicians, 7 th ed. Boca Raton, FL: CRC Press, 2006, pp. 823-844.
6. British Medical Association. Therapeutic Uses of Cannabis. Amsterdam: Harwood Academic Publishers, 1997, pp. 1-6.
7. Royal College of Physicians. Cannabis and Cannabis based medicines: potential benefits and risks to health. Report of a working party. London: RCP, 2005.
8. Dmitrieva N. and Berkley KJ Contrasting effects of WIN 55212-2 on motility of the rat bladder and uterus. J Neurosci 2002 ; 22: 7147-7153.
9. Jaggar SI, Hasnie FS, Sellaturay S. and Rice AS The antihyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998 ; 76: 189-199.
10. Farquhar-Smith WP and Rice AS Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology 2001 ; 94: 507-513.
11. Bartocci C., Evandri MG, Tucci P. and Bolle P. Interactions between delta-9THC and capsaicin on isolated lamb bladder detrusor. Farmaco 2001 ; 56: 349-351.
12. Costa B., Giagnoni G., Franke C., Trovato AE and Calleoni M. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the non-psychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 2004 ; 143: 247-250.
13. Apostolidis A., Yiangou Y., Brady CM, Ford AP, Baecker PA, Jacques TS, et al. Increased urothelial expression of capsaicin receptor TRPV1 in human urinary bladder disorders and decrease after intravesical resiniferatoxin (RTX) treatment. Br J Urol Int 2004 ; 93: 336-340.
14. Hohmann AG and Herkenham M. Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment. Neurosci Lett 1998 ; 252: 13-16.
15. Nicholson AN, Turner C., Stone BM and Robson P. Effect of [DELTA]-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol 2004 ; 24: 305-313.
16. Lastres-Becker I., Molina-Holgado F., Ramos JA, Mechoulam R., Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiology of Disease 2005 ; 19 (1-2). 96-107.
17. Iuvone T., Esposito G., Esposito R., Santamaria R., Di Rossa M. and Izzo AA Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 2004 ; 89: 134-141.
18. Consroe P., Musty R., Rein J., Tillery W. and Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997 ; 38: 44-48.
19. Wagner TH, Patrick DL, Bavendam TG, Martin ML and Buesching DP Quality of life of persons with urinary incontinence: development of a new measure. Urology 1996 ; 47: 67-72.
20. van Leeuwen JH, Castro R., Busse M. and Bemelmans BL The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 2006 ; 50: 440-453.
21. Freeman RM, Adekanmi O., Waterfield MR, Waterfield AE, Wright D. and Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial. Int Urogynecol J Pelvic Floor Dysfunct 2006 ; 17: 636-641.
22. Rog DJ, Nurmikko TJ, Friede T. and Young CA Randomised, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005 ; 65: 812-819.
23. Wade DT, Makela P., Robson P., House H. and Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomised, placebo-controlled study on 160 patients. Mult Scler 2004 ; 10: 434-441.
24. Collin C., Davies P., Mutiboko IK and Ratcliffe S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007 ; 14: 290-296.
25. Barnes MP Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother 2006 ; 7: 607-615.
26. Perras C. Sativex for the management of multiple sclerosis symptoms. Issues Emerg Health Technol 2005 ; 72: 1-4.
27. Nurmikko TJ, Serpell MG and Hoggart B. Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. Pain 2007 ; 133: 210-220.
28. Rog DJ, Nurmikko TJ and Young CA Oromucosal delta-9-tetrahydrocannabinol/ cannabidiol for neuropathic pain associated with Multiple Sclerosis: An uncontrolled, open-label, 2-year extension trial. Clin Ther 2007 ; 20: 2068-2079.
29. Wade DT, Makela PM, House H., Bateman C. and Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006 ; 12: 639-645.
30. Altman D. Assessment of blinding in phase III Sativex spasticity studies. Data on File. (GW Pharma Ltd, 28 July 2006 ).
31. Blyweert W., Van Der Aa F. and De Ridder D. Cannabinoid therapy in detrusor overactivity: local versus systemic effect in a spinalised rat model. Neurol Urodyn 2003 ; 22: 379-380.
32. Ost T., Roskams D. and De Ridder D. Immunohistochemical study of the cannabinoid receptors CB1 and CB2 in the human bladder. Mult Scler 2001 ; S24.
33. Ost F., Van Der Aa F. and De Ridder D. Intravesical application of the endogenous cannabinoid anandamide in the rat model: preliminary data. Mult Scler 2001 ; 7: S17.
34. Avelino A. and Cruz F. TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedebergs Arch Pharmacol 2006 ; 373: 287-299.
35. Merriam FV, Wang ZY, Guerios SD and Bjorling DE Cannabinoid receptor 2 is increased in acutely and chronically inflamed bladder of rats. Neurosci Lett 2008 ; 445: 130-134.
36. Kalsi V., Fowler C. and Dasgupta P. The use of botulinum toxin injections to treat the overactive bladder. ACNR 2005 ; 5: 34-35.